Well Referenced

Category: COVID-19 & Infectious Disease

Strategies for acute care, long-haul management, and immune recovery.

Corrigendum to “A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial”

This corrigendum, published in 2022, addresses corrections to the original 2021 pilot study that evaluated intravenous ozonized saline as an adjunctive treatment for moderate COVID-19 cases. While the specific corrections are not detailed in the available abstract, such corrigenda typically involve amendments to data, authorship, or methodological details. The original

Read More »
June 26, 2025 No Comments

Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations

This 2021 review article explores the potential of methylene blue (MB) as a therapeutic agent for COVID-19, focusing on its mechanisms of action and clinical investigations. MB exhibits multiple antiviral and immunomodulatory properties: it can inhibit SARS-CoV-2 replication by interfering with the viral spike protein’s binding to ACE2 receptors, disrupt

Read More »
June 26, 2025 No Comments

Methylene Blue for Treatment of Hospitalized COVID-19 Patients: A Randomized, Controlled, Open-Label Clinical Trial, Phase 2

This Phase 2 randomized, controlled, open-label clinical trial evaluated the efficacy of oral methylene blue (MB) in hospitalized patients with severe COVID-19. Eighty patients were randomized to receive either MB plus standard of care (SOC) or SOC alone. The MB group showed significant improvements in oxygen saturation (SpO₂) and respiratory

Read More »
June 26, 2025 No Comments

Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial

This Canadian multicenter, open-label randomized controlled trial assessed the efficacy and safety of remdesivir in hospitalized COVID-19 patients. Conducted as part of the WHO Solidarity trial, 1,282 patients were randomized to receive either remdesivir plus standard care or standard care alone. The study found no statistically significant difference in in-hospital

Read More »
June 26, 2025 No Comments

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

This 2020 study by Yao et al. evaluated the antiviral efficacy of hydroxychloroquine (HCQ) against SARS-CoV-2 in vitro and proposed optimized dosing regimens using physiologically based pharmacokinetic (PBPK) modeling. HCQ demonstrated greater potency than chloroquine, with an EC50 of 0.72 μM compared to 5.47 μM. The PBPK model suggested that

Read More »
June 26, 2025 No Comments

RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

This 2020 study by Gautret et al. claimed that hydroxychloroquine, particularly when combined with azithromycin, significantly reduced SARS-CoV-2 viral load in COVID-19 patients. The open-label, non-randomized trial involved 36 participants and reported that the combination therapy led to faster viral clearance compared to controls. However, the study faced immediate criticism

Read More »
June 26, 2025 No Comments

Effect of Early Treatment with Ivermectin among Patients with Covid-19

This multicenter, double-blind, randomized, placebo-controlled trial assessed whether early administration of ivermectin could prevent hospitalization or extended emergency observation in high-risk outpatients with COVID-19. Conducted across 12 public health clinics in Brazil, the study enrolled 3,515 symptomatic adults within 7 days of symptom onset, all possessing at least one risk

Read More »
June 26, 2025 No Comments

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial

This multicenter, double-blind, randomized controlled trial evaluated the efficacy of oral ivermectin in preventing disease progression among adults with mild to moderate COVID-19 and existing comorbidities. Participants were randomly assigned to receive either ivermectin or a placebo, and outcomes such as hospitalization rates, symptom resolution, and adverse events were monitored.

Read More »
June 26, 2025 No Comments

Efficacy and safety of oral ivermectin in the treatment of mild to moderate Covid-19 patients: a multi-centre double-blind randomized controlled clinical trial

This multicenter, double-blind, randomized controlled trial evaluated the efficacy and safety of oral ivermectin in treating patients with mild to moderate COVID-19. Participants were assigned to receive either ivermectin or a placebo, and outcomes such as symptom resolution, viral clearance, hospitalization rates, and adverse events were monitored. The study found

Read More »
June 26, 2025 No Comments

Ivermectin for preventing and treating COVID-19

This comprehensive Cochrane systematic review, updated in June 2022, critically evaluated randomized controlled trials assessing ivermectin’s efficacy and safety for COVID-19 prevention and treatment. The analysis incorporated studies involving both hospitalized and outpatient populations with varying disease severities. Despite initial in vitro findings suggesting antiviral properties, the review found no

Read More »
June 26, 2025 No Comments